Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study

European Heart Journal
Peter E PensonMaciej Banach

Abstract

Recent findings have demonstrated the important contribution of inflammation to the risk of cardiovascular disease (CVD) in individuals with optimally managed low density lipoprotein cholesterol (LDL-C). We explored relationships between LDL-C, high sensitivity C-reactive protein (hs-CRP), and clinical outcomes in a free-living US population. We used data from the REasons for Geographical And Racial Differences in Stroke (REGARDS), and selected individuals at 'high risk' for coronary events with a Framingham Coronary Risk Score of ≥10% or atherosclerotic cardiovascular disease (ASCVD) risk ≥7.5% in order to explore relationships between low LDL-C [<70 mg/dL (1.8 mmol/L) in comparison to ≥70 mg/dL (1.8 mmol/L)]; hs-CRP <2 compared with ≥2 mg/L and clinical outcomes [all-cause mortality, incident coronary heart disease (CHD), and incident stroke]. To assess the association between the LDL-C and hs-CRP categories and each outcome, a series of incremental Cox proportional hazards models were employed on complete cases. To account for missing observations, the most adjusted model was used to interrogate the data using multiple imputation with chained equations (MICE). In this analysis, 6136 REGARDS high-risk participants were includ...Continue Reading

References

Apr 1, 1991·Statistics in Medicine·D B Rubin, N Schenker
Feb 5, 1994·BMJ : British Medical Journal·M R LawN J Wald
Jul 2, 2005·Neuroepidemiology·Virginia J HowardGeorge Howard
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Jan 13, 2011·Statistics in Medicine·Ian R WhiteAngela M Wood
Mar 19, 2011·Annals of Neurology·Virginia J HowardGeorge Howard
Apr 27, 2011·Annals of Neurology·George Howard, David C Goff
Jan 5, 2013·Current Pharmaceutical Design·Manfredi RizzoMaciej Banach
Aug 2, 2014·Journal of the American College of Cardiology·S Matthijs BoekholdtJohn J P Kastelein
Mar 17, 2015·The New England Journal of Medicine·Jennifer G RobinsonUNKNOWN ODYSSEY LONG TERM Investigators
Mar 17, 2015·The New England Journal of Medicine·Marc S SabatineUNKNOWN Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Nov 13, 2015·Expert Opinion on Pharmacotherapy·Maria-Corina SerbanDimitri P Mikhailidis
May 14, 2016·Critical Reviews in Clinical Laboratory Sciences·Kazuhiko KotaniMaciej Banach
Jul 12, 2016·International Journal of Cardiology·Stephen P GlasserMaciej Banach
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
Nov 16, 2016·JAMA : the Journal of the American Medical Association·Stephen J NichollsSteven E Nissen
Jan 10, 2017·Expert Opinion on Investigational Drugs·Peter PensonMaciej Banach
Feb 6, 2017·Journal of the American College of Cardiology·Jennifer G RobinsonJohn J P Kastelein
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Mar 18, 2017·The New England Journal of Medicine·Kausik K RayJohn J P Kastelein
Aug 17, 2017·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN EBBINGHAUS Investigators
Aug 29, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN CANTOS Trial Group

❮ Previous
Next ❯

Citations

Jun 13, 2019·Angiology·Željko ReinerAmirhossein Sahebkar
Dec 26, 2019·International Heart Journal·Yingzhi ChongYong Zhou
Oct 5, 2019·Journal of Clinical Medicine·Ki-Chul SungSang-Baek Ko
Dec 10, 2019·Clinica Chimica Acta; International Journal of Clinical Chemistry·Tomer Ziv-BaranOri Rogowski
Jan 24, 2021·Atherosclerosis·Maciej Banach, Peter E Penson
May 24, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Massimiliano RuscicaCesare R Sirtori
May 11, 2021·Current Atherosclerosis Reports·Maciej Banach, Peter E Penson
May 28, 2021·Stroke; a Journal of Cerebral Circulation·Mu-Hong ChenYa-Mei Bai
Jun 30, 2021·Progress in Cardiovascular Diseases·Massimiliano RuscicaUNKNOWN International Lipid Expert Panel (ILEP) and International Lipid Expert Panel Experts (alphabetically)
Jul 20, 2021·European Cardiology·Ramón Arroyo-EspligueroPablo Avanzas
Sep 2, 2021·Current Atherosclerosis Reports·Neil C HenneyPeter E Penson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.